Pharsight

Camzyos is owned by Bristol.

Camzyos contains Mavacamten.

Camzyos has a total of 2 drug patents out of which 0 drug patents have expired.

Camzyos was authorised for market use on 28 April, 2022.

Camzyos is available in capsule;oral dosage forms.

Camzyos can be used as treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms.

Drug patent challenges can be filed against Camzyos from 2026-04-28.

The generics of Camzyos are possible to be released after 19 June, 2034.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9181200	BRISTOL	Pyrimidinedione compounds	Jun, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9585883	BRISTOL	Pyrimidinedione compounds	Jun, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Apr 28, 2029
New Chemical Entity Exclusivity (NCE)	Apr 28, 2027

Drugs and Companies using MAVACAMTEN ingredient

NCE-1 date: 2026-04-28

Market Authorisation Date: 28 April, 2022

Treatment: Treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms

Dosage: CAPSULE;ORAL